With programs specifically developed for Oracle’s regional customer communities, this multifaceted event provides compelling sessions led by Oracle customers and industry thought leaders.
Meet with your peers and gain perspective on industry trends from leading experts on artificial intelligence, cloud-based research, real-world evidence, innovative study-site selection/activation/analytics, and additional advances that are transforming and streamlining clinical and safety development.
Chicago Theme: See data in new ways, discover insights, and unlock endless possibilities
Inefficiencies in patient recruitment continue to be a prevalent challenge in clinical research and significantly impact all stakeholders of the life sciences industry. Approximately $1.9 billion is spent on recruitment annually and 48% of research sites enroll one or fewer patients for a given trial. Oftentimes, 72% of trial participants are already patients at the site and 28% are new patients. Strong site relationships, deep clinical research expertise, and robust technology is key to achieving better study feasibility and high confidence in the eligibility of enrolled participants.
Senior Director, Learning Health Network
Site selection is a complex process, which includes sites identification, sites assessment, sites validation. and selection of a set of sites aligned with study goals and limited resources. Many factors affect the site selection process. Some of them are generic, others are trial specific. Traditionally, site selection efforts are focused on a selection of optimal clinical sites based on predicted enrollment rates, predicted/planned site capacity, and scoring of multiple site attributes like historical patient enrollment rates. Often, Adding more sites does not solve the problem, because it is associated with increased cost of a clinical trial beyond the budget and inclusion of riskier sites into a pool of feasible sites.
Sr. Director of Product Management, Clinical Trials Planning and Operations Platform, Oracle
The convergence of science and emerging technologies, such as AI and machine learning, is enabling patient-centric approaches to clinical trials with data-driven insights to optimize study design, predict patient responses, improve patient adherence and retention, and to foster inclusiveness and diversity. Capturing the patient voice through the collection of real-world data (eg. EHRs, claims, disease registries, digital health apps, social media) is an integral part of this approach and critical for efficient post-marketing studies. AI-enabled applications and algorithms are also impacting the full lifecycle of therapeutic development, from discovery to commercialization, with the power to find patterns lost by conventional data analysis. Learn how Oracle is helping life science organizations unify data and analytics across the enterprise to unlock the full potential of their mission critical data through our Life Sciences applications, Oracle Cloud Infrastructure, and data & analytics services.
Executive Director, Market Development for Life Sciences
Explore the future of pharmacovigilance including challenges and opportunities faced by safety professionals, and advances in technology that can help address these needs. Join us and our global community of customer advocates and industry leaders at the for in-depth discussions about overcoming challenges specific to gaining insights to stay ahead in this ever-evolving field & ensure optimal patient safety.
Global Head & Strategic Advisor, MultiVigilance Operations, in Oracle Life Sciences Center of Excellence
Oracle is excited and honored to participate in the Cancer Moonshot’s new CancerX public-private partnership. In response to the White House Cancer Moonshot, the Digital Medicine Society (DiMe) and Moffitt Cancer Center currently co-host CancerX, an initiative to rapidly accelerate the pace of cancer innovation in the U.S., alongside the Office of the National Coordinator for Health Information Technology (ONC), and the Office of the Assistant Secretary for Health (OASH). CancerX’s inaugural project focuses on using digital innovation to reduce disparities and financial toxicity in cancer care and research. CancerX uses a three-pronged approach to generate impact in cancer research and care: conducting pre-competitive evidence generation; establishing an accelerator cohort; and leading demonstration projects. The CancerX project team will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey.
Founder of Enlightening Results and co-Founder of Unblock Health
It has been a long-standing industry problem that 50-70% of data collected in EDC is being manually re-entered from EHR systems by Site staff who would rather spend their time on patient care and patient safety. As a result of duplicate data entry, nearly 20-25% of study costs are related to manual transcription, using three minutes per data point (on data entry, validation, correction) and there is an average lost earning per day of $8 million. Oracle aims to address this problem with the acquisition of Cerner and transform the way healthcare data is transferred to clinical trial systems for Clinical research. Our goal is to extract healthcare data from EHR systems in a way so that it can be the bloodline for accelerating clinical trials.
VP, Oracle Clinical Trials
Envision a future where seamless collaboration across the multiomics continuum propels us beyond current boundaries, bridges gaps in research, and creates unprecedented clinical advancements. This transformative collaboration will revolutionize disease prevention and treatment. Join us on a journey through the current genomics landscape, delving into challenges faced by healthcare organizations, patients, and researchers. We will explore the intersection of clinical and research workflows providing a comprehensive understanding of key intersection points. Learn from experts like Terah Collins, Senior Director of Multiomics Products at Oracle about the impact of emerging technologies, from single-cell sequencing to AI driven analytics and how the Oracle Innovation Network aligns individual goals of each segment, driving progress towards unified, improved health.
Senior Director of Multiomic Products
End the day by joining Oracle for a fun filled networking reception with cocktails, conversations, and canapés! Plus join one of our Innovation Lab tours to learn about Oracle’s most cutting-edge technologies.
Today, clinical trial teams and sites rely on a collection of siloed point solutions and disparate data sources, creating redundancy and inefficiency. What if you could build a study once, enter data once, and do everything in one place?
Explore Oracle Life Sciences solutions and resources.